JP2016511752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511752A5 JP2016511752A5 JP2015555389A JP2015555389A JP2016511752A5 JP 2016511752 A5 JP2016511752 A5 JP 2016511752A5 JP 2015555389 A JP2015555389 A JP 2015555389A JP 2015555389 A JP2015555389 A JP 2015555389A JP 2016511752 A5 JP2016511752 A5 JP 2016511752A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- albumin
- pharmaceutical composition
- amino acid
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 118
- 229920001184 polypeptide Polymers 0.000 claims description 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 117
- 102000009027 Albumins Human genes 0.000 claims description 52
- 108010088751 Albumins Proteins 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 22
- 102000008300 Mutant Proteins Human genes 0.000 claims description 16
- 108010021466 Mutant Proteins Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 230000000704 physical effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 230000004988 N-glycosylation Effects 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758456P | 2013-01-30 | 2013-01-30 | |
| US61/758,456 | 2013-01-30 | ||
| US201361882542P | 2013-09-25 | 2013-09-25 | |
| US61/882,542 | 2013-09-25 | ||
| PCT/US2014/013232 WO2014120619A2 (en) | 2013-01-30 | 2014-01-27 | Compositions and methods of use in treating metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511752A JP2016511752A (ja) | 2016-04-21 |
| JP2016511752A5 true JP2016511752A5 (enExample) | 2016-10-27 |
| JP6272907B2 JP6272907B2 (ja) | 2018-01-31 |
Family
ID=51263106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555389A Expired - Fee Related JP6272907B2 (ja) | 2013-01-30 | 2014-01-27 | 代謝障害の処置における組成物及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9828415B2 (enExample) |
| EP (1) | EP2950807B1 (enExample) |
| JP (1) | JP6272907B2 (enExample) |
| KR (1) | KR101993714B1 (enExample) |
| AU (1) | AU2014212640B2 (enExample) |
| BR (1) | BR112015018104A2 (enExample) |
| CA (1) | CA2899170C (enExample) |
| RU (1) | RU2704285C2 (enExample) |
| WO (1) | WO2014120619A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2403964B1 (en) | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| ES2881535T3 (es) | 2011-03-15 | 2021-11-29 | Massachusetts Inst Technology | Detección multiplexada con indicadores codificados con isótopos |
| WO2013113008A1 (en) | 2012-01-26 | 2013-08-01 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| WO2014197840A1 (en) | 2013-06-07 | 2014-12-11 | Massachusetts Institute Of Technology | Affinity-based detection of ligand-encoded synthetic biomarkers |
| UA116665C2 (uk) * | 2013-07-31 | 2018-04-25 | Емджен Інк. | Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20170204149A1 (en) * | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
| SG11201609706VA (en) * | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
| CN106459222A (zh) | 2014-06-24 | 2017-02-22 | 诺和诺德股份有限公司 | Mic‑1融合蛋白及其用途 |
| TN2016000578A1 (en) | 2014-07-30 | 2018-04-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| CA2964808C (en) * | 2014-10-30 | 2023-06-27 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| EP3212226B1 (en) * | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| JP2018502908A (ja) * | 2014-12-22 | 2018-02-01 | ノヴォ ノルディスク アー／エス | アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用 |
| WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| CN108367053A (zh) * | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| EP3440013A4 (en) * | 2016-04-08 | 2021-03-17 | Massachusetts Institute of Technology | METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES |
| CA3022928A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| MA45113A (fr) | 2016-05-24 | 2019-04-10 | Novo Nordisk As | Composés mic-1 et leur utilisation |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| EP3515928B1 (en) | 2016-09-23 | 2026-01-28 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS |
| CN111163795A (zh) | 2017-09-10 | 2020-05-15 | 诺沃挪第克公司 | 用于治疗肥胖症的mic-1和glp-1 |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| PE20201350A1 (es) * | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| JP2021533743A (ja) | 2018-08-10 | 2021-12-09 | ノバルティス アーゲー | Ｇｆｒａｌ細胞外ドメイン及び使用方法 |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| AU2019368816B2 (en) * | 2018-10-22 | 2025-01-30 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof |
| WO2020150560A1 (en) | 2019-01-17 | 2020-07-23 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
| EP3920955A4 (en) * | 2019-02-05 | 2023-02-22 | The Trustees of the University of Pennsylvania | GDNF FAMILY RECEPTOR-A-LIKE PEPTIDE LIGANDS (GFRAL) |
| EP3934679A1 (en) * | 2019-03-08 | 2022-01-12 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
| AU2020260931B2 (en) * | 2019-04-23 | 2023-08-24 | Lg Chem, Ltd. | Fusion polypeptide comprising Fc region of immunoglobulin and GDF15 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| KR20210065057A (ko) * | 2019-11-26 | 2021-06-03 | 주식회사유한양행 | 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물 |
| WO2021178481A1 (en) * | 2020-03-04 | 2021-09-10 | Duke University | Protein nanoparticle design and application |
| EP4237438A4 (en) * | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| JPH07258293A (ja) * | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| EP0833912B1 (en) | 1995-06-22 | 2009-02-25 | St Vincent's Hospital Sydney Limited | Novel tgf-beta like cytokine |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| WO1998011224A1 (en) | 1996-09-11 | 1998-03-19 | Ortho-Mcneil Pharmaceutical,Inc | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| WO2000005259A1 (en) | 1998-07-23 | 2000-02-03 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ATE348164T1 (de) | 1999-05-17 | 2007-01-15 | Bioph Biotech Entw Pharm Gmbh | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| EP1914554B1 (en) | 2000-04-20 | 2010-06-09 | St Vincent's Hospital Sydney Limited | Diagnostic assay involving macrophage inhibitory cytokine-1 (MIC-1) |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| CA2433439A1 (en) | 2000-12-29 | 2002-08-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
| HU229910B1 (hu) | 2001-05-11 | 2014-12-29 | Amgen Inc Thousand Oaks | A TALL-1-hez kötõdõ peptidek és rokon molekulák |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| US20040253207A1 (en) | 2002-11-08 | 2004-12-16 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
| JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
| HRP20160990T1 (hr) | 2006-03-24 | 2016-10-07 | Biogen Hemophilia Inc. | Pc5 kao enzim obrade faktor ix propeptida |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| MX2008015263A (es) | 2006-06-02 | 2008-12-17 | Wyeth Corp | Uso de proteinas y pepetidos de la superfamilia del factor beta transformador de crecimiento para purificacion y metodos terapeuticos. |
| EP2052253A2 (en) * | 2006-07-26 | 2009-04-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
| WO2008015254A2 (en) | 2006-08-04 | 2008-02-07 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| CN101808672B (zh) | 2007-04-25 | 2013-05-01 | 干细胞旋转股份公司 | 干细胞系、其应用以及培养方法 |
| CA2720628A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| EP2783698A1 (en) | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
| US20100266707A1 (en) | 2007-10-09 | 2010-10-21 | Samuel Norbert Breit | Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| WO2009052557A1 (en) | 2007-10-22 | 2009-04-30 | St Vincent's Hospital Sydney Limited | Methods of prognosis |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2227696A1 (en) | 2008-01-08 | 2010-09-15 | Roche Diagnostics GmbH | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 |
| JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５ |
| JP2011528115A (ja) | 2008-07-14 | 2011-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| MX2011004563A (es) | 2008-10-31 | 2011-06-01 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| WO2010093925A2 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| US8952130B2 (en) * | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| TWI560197B (en) * | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| MX2011013455A (es) | 2009-07-08 | 2012-02-13 | Amgen Inc | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. |
| WO2011008956A2 (en) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Mammalian genes involved in infection |
| WO2011050407A1 (en) * | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Methods of diagnosing and prognosing colonic polyps |
| SI2496601T1 (sl) | 2009-11-05 | 2017-09-29 | F. Hoffmann-La Roche Ag | Tehnike in sestavek za sekrecijo heterolognih polipeptidov |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
| US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| EP2609427B1 (en) | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| JP5997151B2 (ja) | 2011-06-30 | 2016-09-28 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| WO2013113008A1 (en) * | 2012-01-26 | 2013-08-01 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| BR112015002085A2 (pt) | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| PE20151673A1 (es) | 2013-03-15 | 2015-11-27 | Genentech Inc | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO |
| UA116665C2 (uk) | 2013-07-31 | 2018-04-25 | Емджен Інк. | Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| TN2016000578A1 (en) | 2014-07-30 | 2018-04-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| EP3212226B1 (en) | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
-
2014
- 2014-01-27 EP EP14746188.3A patent/EP2950807B1/en not_active Not-in-force
- 2014-01-27 BR BR112015018104A patent/BR112015018104A2/pt not_active IP Right Cessation
- 2014-01-27 CA CA2899170A patent/CA2899170C/en active Active
- 2014-01-27 AU AU2014212640A patent/AU2014212640B2/en not_active Ceased
- 2014-01-27 WO PCT/US2014/013232 patent/WO2014120619A2/en not_active Ceased
- 2014-01-27 KR KR1020157023041A patent/KR101993714B1/ko not_active Expired - Fee Related
- 2014-01-27 RU RU2015136440A patent/RU2704285C2/ru active
- 2014-01-27 US US14/763,262 patent/US9828415B2/en not_active Expired - Fee Related
- 2014-01-27 JP JP2015555389A patent/JP6272907B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-20 US US15/789,679 patent/US10323075B2/en active Active
-
2019
- 2019-04-29 US US16/397,578 patent/US20200087366A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,984 patent/US20210388047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| JP2017529059A5 (enExample) | ||
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| CN102131516B (zh) | 包含弹性蛋白样肽的治疗剂 | |
| AU2015296640B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP6618854B2 (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| JP6169079B2 (ja) | 徐放のための活性剤の製剤 | |
| JP2021184727A (ja) | 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物 | |
| CA2862516A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2017538395A5 (enExample) | ||
| TW201602345A (zh) | 生長分化因子１５（ｇｄｆ－１５）構築體 | |
| JP2017538395A (ja) | 代謝障害を処置するための組成物及びその使用方法 | |
| MX2014012625A (es) | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. | |
| US20220235111A1 (en) | Variant Single-Chain Insulin Analogues | |
| CN105025919A (zh) | 用于血糖控制的治疗剂、组合物和方法 | |
| WO2011060583A1 (zh) | 非天然的胶原样蛋白及其应用 | |
| WO2020015677A1 (zh) | 长效纤连蛋白iii型结构域融合蛋白 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| AU2020279968B2 (en) | Variant single-chain insulin analogues | |
| WO2024141054A1 (zh) | 包含融合蛋白的药物组合物及其用途 | |
| HK1223556A1 (zh) | Il-22二聚体在制备用於治疗胰腺炎的药物中的用途 |